Stockscreener 앱 받기
1.67
1.21%
0.02
전일 마감가:
$1.65
열려 있는:
$1.66
하루 거래량:
318.57K
Relative Volume:
0.79
시가총액:
$202.52M
수익:
-
순이익/손실:
$-19.57M
주가수익비율:
-0.5335
EPS:
-3.13
순현금흐름:
$-17.24M
1주 성능:
-2.62%
1개월 성능:
+4.37%
6개월 성능:
-10.22%
1년 성능:
-39.49%
1일 변동 폭
$1.63
$1.72
1주일 범위
$1.63
$1.7267
52주 변동 폭
$1.33
$3.32
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
명칭
Inhibikase Therapeutics Inc
전화
(302) 295-3800
주소
1000 N. WEST STREET, SUITE 1200, WILMINGTON
IKT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.67 | 200.09M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-26 | 개시 | H.C. Wainwright | Buy |
| 2025-12-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-02-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc 주식(IKT)의 최신 뉴스
Take Profit: Why Inhibikase Therapeutics Inc stock could outperform in 2025 - Bộ Nội Vụ
Published on: 2026-01-14 00:17:08 - Bộ Nội Vụ
How Inhibikase Therapeutics Inc IQT0 stock reacts to stronger dollarSwing Trade & Growth Focused Investment Plans - Bộ Nội Vụ
Why Inhibikase Therapeutics Inc. stock attracts global investorsBest Sellers Snapshot & trail grip notes for mixed terrain - Улправда
How Inhibikase Therapeutics Inc. stock performs in weak economyMarket Weekly Review & Technical Entry and Exit Tips - Улправда
Is Inhibikase Therapeutics Inc. stock attractive for passive investorsPortfolio Update Report & Weekly Watchlist of Top Performers - ulpravda.ru
Can Inhibikase Therapeutics Inc. stock sustain institutional interestJuly 2025 PostEarnings & Stepwise Trade Execution Plans - Улправда
How Inhibikase Therapeutics Inc. (IQT0) stock reacts to stronger dollarWeekly Loss Report & Safe Entry Point Identification - Улправда
Can Inhibikase Therapeutics Inc. (IQT0) stock surprise with quarterly results2025 Key Lessons & Low Drawdown Trading Strategies - Улправда
Published on: 2026-01-08 18:28:15 - ulpravda.ru
What analyst consensus says on Inhibikase Therapeutics Inc. stockGap Up & Safe Swing Trade Setup Alerts - Улправда
Inhibikase Halts Parkinson's Drug Development to Focus on PAH - MSN
Is Inhibikase Therapeutics Inc. stock attractive for income investorsHealthcare Stock Analysis & Budget Investment Success - Улправда
Laser Focus WorldInhibikase Therapeutics, Inc.Common Stock (Nasdaq:IKT) Stock Quote - FinancialContent
Dopamine Agonists Market is expected to reach US$ 1,732.41 - openPR.com
Inhibikase Therapeutics (NYSE:IKT) & Alpha Cognition (OTC:ACOGF) Head-To-Head Review - Defense World
Critical Survey: Liminatus Pharma (NASDAQ:LIMN) vs. Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Comparing Liminatus Pharma (NASDAQ:LIMN) & Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
While Institutions Invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Benefited From Last Week's 24% Gain, Retail Investors Stood to Gain the Most - 富途牛牛
Short Interest in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Rises By 29.0% - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) vs. Liminatus Pharma (NASDAQ:LIMN) Financial Survey - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of “Buy” by Analysts - Defense World
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path By Investing.com - Investing.com Nigeria
Jefferies reiterates Buy rating on Inhibikase stock, citing faster FDA path - Investing.com Nigeria
Inhibikase Therapeutics (NASDAQ:IKT) Raised to “Strong-Buy” at HC Wainwright - Defense World
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Raised to "Strong-Buy" at HC Wainwright - MarketBeat
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to Sell at Wall Street Zen - Defense World
Inhibikase Therapeutics (NYSE:IKT) Receives Buy Rating from HC Wainwright - MarketBeat
H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright assumes coverage on Inhibikase stock with Buy rating - Investing.com
Inhibikase Therapeutics (IKT): HC Wainwright & Co. Issues 'Buy' Rating | IKT Stock News - GuruFocus
Contrasting Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN) - Defense World
Inhibikase Therapeutics (IKT) price target decreased by 20.00% to 5.71 - MSN
Inhibikase Therapeutics Announces $93.6 Million Stock Offering - MSN
Contrasting Inhibikase Therapeutics (NYSE:IKT) and Sorrento Therapeutics (NASDAQ:SRNE) - Defense World
Is Inhibikase Therapeutics Inc. stock a safe buy before earningsOptions Trading Strategies & Low Risk Trading Growth - bollywoodhelpline.com
Inhibikase Therapeutics (NASDAQ:IKT) and Liminatus Pharma (NASDAQ:LIMN) Head to Head Contrast - Defense World
Analyzing Liminatus Pharma (NASDAQ:LIMN) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
Can Inhibikase Therapeutics Inc. stock double in next 5 years2025 Technical Patterns & Free Weekly Chart Analysis and Trade Guides - Улправда
Gains Report: Why Inhibikase Therapeutics Inc. stock remains a top recommendationEarnings Summary Report & Low Risk High Reward Trade Ideas - moha.gov.vn
Will Inhibikase Therapeutics Inc. stock sustain high P E ratios2025 Market Sentiment & Growth Focused Stock Reports - Улправда
Inhibikase Updates ATM Equity Program to Raise Capital - The Globe and Mail
Inhibikase Therapeutics Earnings Notes - Trefis
Inhibikase Therapeutics Updates ATM Offering Program - TradingView — Track All Markets
Is Inhibikase Therapeutics Inc. stock recession proofJuly 2025 Sentiment & Safe Entry Trade Signal Reports - DonanımHaber
Why Inhibikase Therapeutics Inc. stock remains a top recommendationQuarterly Performance Summary & Momentum Based Trading Signals - DonanımHaber
Dow Update: Is Inhibikase Therapeutics Inc. stock attractive for hedge fundsJuly 2025 Big Picture & Reliable Volume Spike Alerts - Улправда
What drives Inhibikase Therapeutics Inc stock priceVolume Weighted Average Price & Free Stock Index Interpretations - earlytimes.in
While institutions invested in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) benefited from last week's 11% gain, individual investors stood to gain the most - simplywall.st
Inhibikase Therapeutics Inc (IKT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):